Ticker
ALDX

Price
6.19
Stock movement up
+0.01 (0.16%)
Company name
Aldeyra The
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
362.49M
Ent value
261.33M
Price/Sales
-
Price/Book
2.23
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
79.94%
3 year return
3.33%
5 year return
-2.71%
10 year return
-
Last updated: 2023-02-06

DIVIDENDS

ALDX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.23
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count58.56M
EPS (TTM)-1.11
FCF per share (TTM)-728.22

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-64.39M
Net income (TTM)-64.88M
EPS (TTM)-1.11
EPS (1y forward)-1.32

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash128.65M
Net receivables21.50M
Total current assets189.48M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets189.69M
Accounts payable1.31M
Short/Current long term debt15.94M
Total current liabilities24.20M
Total liabilities27.50M
Shareholder's equity162.19M
Net tangible assets162.19M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-56.98M
Capital expenditures (TTM)32.63K
Free cash flow (TTM)-42.57B
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-40.00%
Return on Assets-34.20%
Return on Invested Capital-36.42%
Cash Return on Invested Capital-23898.43%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open6.15
Daily high6.29
Daily low6.12
Daily Volume210K
All-time high14.85
1y analyst estimate19.88
Beta1.14
EPS (TTM)-1.11
Dividend per share-
Ex-div date-
Next earnings date15 Mar 2023

Downside potential

Loading...
Downside potential data
ALDXS&P500
Current price drop from All-time high-58.32%-14.21%
Highest price drop-88.71%-56.47%
Date of highest drop16 Mar 20209 Mar 2009
Avg drop from high-46.60%-11.49%
Avg time to new high122 days13 days
Max time to new high919 days1805 days
COMPANY DETAILS
ALDX (Aldeyra The) company logo
Marketcap
362.49M
Marketcap category
Small-cap
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Employees
15
Investor relations
-
SEC filings
CEO
Todd C. Brady
Country
USA
City
Lexington
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
LEXINGTON, Mass., February 07, 2023--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) fo...
February 7, 2023
Insiders who bought Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) in the last 12 months may probably not pay attention to...
January 12, 2023
LEXINGTON, Mass., December 21, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) f...
December 21, 2022
Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629. Relative to the placebo, AD...
December 13, 2022
LEXINGTON, Mass., December 13, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced demonstration of target engagement and improvement in the signs of alcohol intoxication in a se...
December 13, 2022
LEXINGTON, Mass., December 01, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) ...
December 1, 2022
LEXINGTON, Mass., November 29, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) f...
November 29, 2022
LEXINGTON, Mass., November 10, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated disea...
November 10, 2022
LEXINGTON, Mass., November 03, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, November 10, 2022 to report financial results for the qua...
November 3, 2022
Aldeyra Therapeutics Inc. develops innovative therapies designed to treat immune-mediated diseases. In this daily bar chart of ALDX, below, we can see that ALDX had a rocky path to a low in May. Pri...
November 2, 2022
Next page